Company Encyclopedia
View More
name
Daiichi Sankyo Company, Limited
4568.JP
News
View More

General Proximity, Daiichi Sankyo Partner to Advance Novel Oncology Therapeutics Using OmniTAC

General Proximity:GENERAL PROXIMITY ANNOUNCES MULTI-TARGET COLLABORATION WITH DAIICHI SANKYO TO DISCOVER AND ADVANCE NOVEL ONCOLOGY THERAPEUTICS USING OMNITAC™ PLATFORM

Reuters·
US
DSNKY
+1.76%
Reuters·
US
DSNKY
+1.76%

Datroway Plus Rilvegostomig Showed Promising Tumor Responses In Tropion-Pantumor03 Phase 2 Trial

Daiichi Sankyo Co Ltd :DATROWAY® PLUS RILVEGOSTOMIG SHOWED PROMISING TUMOR RESPONSES IN PATIENTS WITH METASTATIC UROTHELIAL CANCER IN TROPION-PANTUMOR03 PHASE 2 TRIALDAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SHOWS 68.2% RESPONSE RATEDAIICHI SANKYO CO LTD - DATROWAY PLUS RILVEGOSTOMIG SAFETY PROFILE CONSISTENT

Reuters·
US
DSNKY
+1.76%
Reuters·
US
DSNKY
+1.76%

Enhertu® Followed Biologics License Application Accepted In The U.S. For Patients With Early-Stage Breast Cancer Prior To Surgery

Oct 1 (Reuters) - Daiichi Sankyo Co Ltd (4568.T) :* ENHERTU® FOLLOWED BY THP SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION ACCEPTED IN THE U.S. FOR PATIENTS WITH HIGH-RISK HER2 POSITIVE EARLY-STAGE BREAST CANCER PRIOR TO SURGERY* DAIICHI SANKYO CO LTD - FDA TARGET ACTION DATE FOR ENHERTU IS MAY 18, 2026 Source text: Further company coverage: (4568.T)

Reuters·
4568
0.00%
US
DSNKY
+1.76%
Reuters·
4568
0.00%
US
DSNKY
+1.76%